Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sarcoma Alliance for Research through Collaboration
With
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Unresectable and/or metastatic GIST
Currently receiving imatinib 400 mg per day for a minimum of 4 weeks prior to registration, and for no more than 6 months prior to registration. This must be the first time that the patient has been treated for metastatic and/or unresectable GIST
For patients who received imatinib following surgery at the time of an initial diagnosis of GIST, there must be a 6 month interval between completion of imatinib and the diagnosis of metastatic GIST
Good physical functioning (ECOG Performance Status of 0 or 1)
Generally, good function of organ such as liver and kidneys
You may not be if
Disease progression during adjuvant therapy with imatinib (adjuvant treatment is treatment that is given after surgery for GIST)
Known intolerance of imatinib at a dose of 400 mg/day or higher
Prior systemic therapy for advanced GIST with imatinib or those who have been on imatinib for longer than 6 months for unresectable and/or metastatic disease
Major surgery within 2 weeks prior to Day 1 of study or who have not yet recovered from prior surgery
Use of coumadin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)
Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation \< 2 weeks or who have not recovered from side effects of this therapy
Clareo Health | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
